BI study: No drug interaction between Aggrenox, omeprazole

RIDGEFIELD, Conn. — An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

The drug maker — which presented the multiple-dose, open-label, randomized crossover study (that included 60 healthy subjects) at the International Stroke Conference in New Orleans — examined the interaction between Aggrenox (aspirin/extended-release dipyridamole) capsules in the 25-mg/200-mg strength and omeprazole. The drug maker said that it wanted to show that while omeprazole is shown to interact with some medications, it did not interact with Aggrenox.

“Omeprazole has been shown to interact with some medications that are metabolized through the CYP2C19 system. Aggrenox is not metabolized through the CYP2C19 system, however we wanted to understand if it would be affected when given together with omeprazole,” said John Smith, SVP clinical development and medical affairs at Boehringer Ingelheim. “We are pleased that these data have shown that omperazole does not interact with Aggrenox.”

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.